Email this article 
FARMAKOTERAPIYa MIGRENI. NASTOYaShchEE I BUDUShchEE
- Authors: Iskra DA1
-
Affiliations:
- ВМедА им. С.М. Кирова
- Issue: Vol 20, No 3S (2018)
- Pages: 52-54
- Section: Articles
- URL: https://journals.rcsi.science/1682-7392/article/view/13207
- ID: 13207
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##References
- осипова В.В. Диагностика и лечение мигрени в амбулаторной практике (клинические рекомендации для неврологов и вра- чей общей практики) / В.В. осипова. - М.: ИМА-ПРеСС, 2016. - 36 с.
- табеева, Г.Р. Мигрень / Г.Р. табеева, Н.Н. Яхно. - М. : ГЭотАР-Медиа, 2011. - 622 с.
- Филатова, е.Г. терапия приступов мигрени / е.Г. Филатова // Русский медицинский журнал. - 2013. - т. 21, №16. - С. 862-865.
- Chizh, B.A. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans / B.A. Chizh [et al.] // Pain. - 2007. - Vol. 132. - Р. 132-141.
- Farkkila, M. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study / M. Farkkila [et al.] and the COL MIG-202 study group. // Lancet Neurol. - 2012. - Vol.11. - Р. 405-413.
- Hougaard, A. The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: a randomized, double-blind, placebo-controlled cross-over study / A. Hougaard [et al.] // Scan J Pain. - 2012. - Vol.4. - Р. 48-52.
- Gomez-Mancilla, B. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks / B. Gomez-Mancilla [et al.] and the BGG492 Study Group // Cephalalgia. - 2014. - Vol.34. - Р. 103-113.
- Wrobel Goldberg, S. Targeting CGRP: A New Era for Migraine Treatment / S. Wrobel Goldberg, S.D. Silberstein // CNS Drugs. - 2015. - Vol. 29, №6. - Р. 443-452.
